Home
NewsNewsMochida Grants LG Chem Endometriosis Drug Licensing to develop and sell Dinagest that has an active ingredient, Dienogest, that halts endometrial cells from growing, offering a non-hormonal therapeutic option for women suffering from endometriosis.
Mochida Pharmaceutical, which is based in Japan, and LG Chem, which is based in South Korea, have made a deal to work together on Dinagest. Mochida sells Dinagest in Japan, where it is used to treat endometriosis as well as other conditions.
As part of the endometriosis drug licensing deal, Mochida has given LG Chem exclusive rights to develop and sell the product in South Korea and Thailand. LG Chem will get the necessary marketing approvals in each country and then make the product available to patients.
Dienogest, the active ingredient in Dinagest, is a progestin that stops the ovaries from working and halts endometrial cells from growing by selectively binding to the progesterone receptor.
Mochida introduced the product in Japan in 2008 and has been looking for ways to expand it into other countries. Mochida has also been working to grow its business operations around the world by 2031. As a result of these efforts, Mochida is moving forward with the product's first global expansion as part of this agreement.
For more than 30 years, LG Chem has been an expert in the research and production of hormone-based therapies for infertility treatment in the field of reproductive medicine. LG Chem continues to be a trusted partner in the field of reproductive medicine because it has high-quality products, does ongoing research and development, and is very dedicated to patients and doctors.
With Endometriosis Drug Licensing, Mochida has given LG Chem exclusive rights to develop and sell Dinagest. Apparently, both companies have worked together before on the biosimilars of etanercept and adalimumab. These products were subsequently released in Japan. Mochida and LG Chem want to get the product to patients in South Korea and Thailand and help them live better lives by way of this new agreement.
Legacy, North America's leading digital male fertility clinic, has secured New York State CLEP approval for both its semen analysis and DNA fragmentation test – the only mandatory pre-market laboratory review programme in the United States. The approvals confirm clinical-grade validity for at-home samples, extending access to New York patients without a clinic visit.
From 1 July 2026, South Australia's Fertility Treatment Rebate Scheme provides eligible residents with a $250 rebate for pre-treatment testing and a $2,000 rebate for up to two fertility treatment cycles. Backed by an $18.5 million, four-year government commitment, the scheme directly addresses the financial barriers preventing South Australians from accessing fertility care.
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
